Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMBER-3 phase 3 study of imlunestrant versus investigator's choice endocrine therapy, and imlunestrant + abemaciclib in ER-positive, HER2-negative advanced or metastatic breast cancer
CTR20221699Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of imlunestrant, abemaciclib, fulvestrant, exemestane in breast cancer, sponsored by Eli Lilly and Company. Started Nov 2022; status: active.
02
Drugs
imlunestrantabemaciclibfulvestrantexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20221699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221699.